Investor Relations

Esperion Therapeutics, Inc. is an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers.

Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 4:00 PM ET on May 22, 2015
Last Price Change Open Day High 52-Week High
5.83  down   (5.124%) 107.89 109.72 120.96
Volume Previous Close Day Low 52-Week Low
2,012,300 113.77 101.10 13.90

View all »   RSSRecent Releases

May 11, 2015
Esperion Therapeutics to Present at the UBS Global Healthcare Conference

May 7, 2015
Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports First Quarter 2015 Financial Results